Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Kiessling

Family Medicine Anchorage, AK Medical Doctor

NPI 1386608156 CMS profile 62594

4100 Lake Otis Pkwy, Ste. 322, Anchorage, AK 99508

Open in the dashboard

General payments

$4,890

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Kiessling of Anchorage, AK is reported in the CMS Open Payments database as having received $4,890 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2023 General $230 12
2022 General $752 42
2021 General $1,397 83
2020 General $1,185 67
2019 General $1,305 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Kiessling
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Bruce Kiessling were reported at $20. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Bruce Kiessling Family Medicine median Middle half National median
2019 $1,305 $150 $41–$543 $163
2020 $1,185 $120 $32–$415 $114
2021 $1,397 $137 $35–$551 $132
2022 $752 $137 $37–$512 $149
2023 $230 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $20 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $791 41 payments
  2. AbbVie, Inc. $613 31 payments
  3. GlaxoSmithKline, LLC. $462 33 payments
  4. Allergan Inc. $360 13 payments
  5. Novo Nordisk Inc $350 27 payments
  6. Lilly USA, LLC $237 16 payments
  7. Amarin Pharma Inc. $218 12 payments
  8. Astellas Pharma US Inc $214 12 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $201 9 payments
  10. Novartis Pharmaceuticals Corporation $181 12 payments
  11. Other $1,263 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,890 287 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $405 17 payments
  2. UBRELVY $347 14 payments
  3. TRELEGY ELLIPTA $259 17 payments
  4. MYRBETRIQ $214 12 payments
  5. Vascepa $199 11 payments
  6. SYMBICORT $197 11 payments
  7. TRULICITY $196 13 payments
  8. SPIRIVA RESPIMAT $188 8 payments
  9. JARDIANCE Diabetes $183 8 payments
  10. JARDIANCE Diabetes $180 12 payments
  11. Other $4,183 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record